Orthocell to release March quarterly results, host investor webinar on April 20

The webinar volition screen its quarterly results and supply an operational update, including advancement connected the US rollout of Remplir and its usage successful prostate crab surgeries successful Australia.

Orthocell seat John Van Der Wielen, CEO and managing manager Paul Anderson, and CFO Jim Piper volition contiguous the briefing.

The webinar is scheduled for 9am AWST / 11am AEDST connected Monday, 20 April 2026.

Register now: https://Orthocell Ltd/Webinar/March Quarter/Register

Orthocell is opening to make commercialized momentum from its enlargement into the US market, marking a cardinal measurement successful the company’s long-flagged displacement towards broader income growth.

After respective years of merchandise development, regulatory approvals and aboriginal offshore sales, Orthocell is present establishing a beingness for its nervus repair instrumentality Remplir successful the US, its largest imaginable marketplace and 1 of its astir competitive. Early signs of adoption crossed hospitals and surgeons, including repetition use, constituent to increasing traction arsenic the institution scales the rollout.

The accidental is drafting attraction to a large-volume country of country that remains comparatively underpenetrated by precocious repair devices, with Orthocell indicating that adjacent humble gains successful uptake could enactment meaningful gross growth.